Bennett H. Brosnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bennett H. Brosnan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa J. Cozzo
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
1 shared publication - Alyssa N. Ho
Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina
1 shared publication - Claire E. Gates
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
1 shared publication - Elaine M. Glenny
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
1 shared publication - Michael Francis Coleman
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
1 shared publication - Scott P. Connelly
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
1 shared publication
Latest Publications
- Open Access
Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) lacks targeted therapies, leaving cytotoxic chemotherapy as the current standard treatment. However, chemotherapy resistance remains a major clinical challenge. Increased insulin-like growth factor 1 signaling can potently blunt chemotherapy response, and lysosomal processes including the nutrient scavenging pathway autophagy can enable cancer cells to evade chemotherapy-mediated cell death. Thus, we tested whether inhibition of insulin receptor/insulin-like growth factor 1 receptor with the drug BMS-754807 and/or lysosomal disruption with hydroxychloroquine (HCQ) could sensitize TNBC cells to the chemotherapy drug carboplatin. Using in vitro studies in multiple TNBC cell lines, in concert with in vivo studies employing a murine syngeneic orthotopic transplant model of TNBC, we show that BMS-754807 and HCQ each sensitized TNBC cells and tumors to carboplatin and reveal that exogenous metabolic modulators may work synergistically with carboplatin as indicated by Bliss analysis. Additionally, we demonstrate the lack of overt in vivo toxicity with our combination regimens and, therefore, propose that metabolic targeting of TNBC may be a safe and effective strategy to increase sensitivity to chemotherapy. Thus, we conclude that the use of exogenous metabolic modulators, such as BMS-754807 or HCQ, in combination with chemotherapy warrants additional study as a strategy to improve therapeutic responses in women with TNBC.
Open AccessExogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) lacks targeted therapies, leaving cytotoxic chemotherapy as the current standard treatment. However, chemotherapy resistance remains a major clinical challenge. Increased insulin-like growth factor 1 signaling can potently blunt chemotherapy response, and lysosomal processes including the nutrient scavenging pathway autophagy can enable cancer cells to evade chemotherapy-mediated cell death. Thus, we tested whether inhibition of insulin receptor/insulin-like growth factor 1 receptor with the drug BMS-754807 and/or lysosomal disruption with hydroxychloroquine (HCQ) could sensitize TNBC cells to the chemotherapy drug carboplatin. Using in vitro studies in multiple TNBC cell lines, in concert with in vivo studies employing a murine syngeneic orthotopic transplant model of TNBC, we show that BMS-754807 and HCQ each sensitized TNBC cells and tumors to carboplatin and reveal that exogenous metabolic modulators may work synergistically with carboplatin as indicated by Bliss analysis. Additionally, we demonstrate the lack of overt in vivo toxicity with our combination regimens and, therefore, propose that metabolic targeting of TNBC may be a safe and effective strategy to increase sensitivity to chemotherapy. Thus, we conclude that the use of exogenous metabolic modulators, such as BMS-754807 or HCQ, in combination with chemotherapy warrants additional study as a strategy to improve therapeutic responses in women with TNBC.